ACUTE MYELOGENOUS LEUKEMIA (AML)
|
|
|
- Myrtle Cole
- 10 years ago
- Views:
Transcription
1 Nicole Pearsall Clonal hematopoietic Disorders V Dr. Silberstein (#19) 9/23/03 The first 2 pages of Dr. Silberstein s notes are according to him the Gospel. This is what we are suppose to know for exam purposes. Since that is what we are all interested in I have retyped the first two pages below for quick reference. Following is the rest of his lecture. He will not hold us accountable for drugs except what is on the first two pages. Thank GOD! He only made a few comments about his power point presentation and mainly referred back to his first two pages so know those already, okay. Here we go! Myeloproliferatvie disorders 1. Chronic Myelogenous Leukemia (CML) -Philadelphia Chromosome (9,22) -Goal treatment is prevent blast crisis -Gleevec (tyrosine kinase inhibitor) very effective -Blood smear: increased myeloid line (polys, bands, metamyelocytes, myelocytes, promyelocytes) and basophils, and eosinophils 2. Polycythemia Vera -Decreased serum erythropoietin lvl (distinguish from secondary polycythemia) -Increased risk of clotting (stroke) -Goal therapy reduce Hct < 45% to reduce risk of clotting -Rx: Phlebotomy or Hydroxyurea 3. Essential Thrombocytosis -Elevated platelet ct. often > 1 million -Untreated pts. can bleed or clot -Low risk pts don t need treatment -Hi risk pts. w/ risk factors for vascular disease and stroke -Rx: hydroxyurea or anagrelide 4. Agnogeneic Myeloid Metaplasia (Myelofiborsis) -Bone marrow full of fibrosis tissue (scar) -Splenomegaly -Difficult to treat; need transfusion ACUTE MYELOGENOUS LEUKEMIA (AML) Poor prognosis w/ older age or prior history of myelodysplastic syndrome (pre-lukemia) Splenomegaly is uncommon Chemo: Cyarabine (Ara-C) + an anthracycline (Daunorubicin or Idarubicin) High Dose Ara-C w/ consolidation or relapse Induction therapy will cause complete remission in most pts., but w/out consolidation therapy, most pts. will relaspse and require reinduction Rx. Mylotarg (specific antibody therapy)- new therapy in cancer. Antibody linked w/a posion which goes right to the cancer cells and kills them. Antibody against CD33 Linked w/ potent-anti tumor antibiotic called calicheamicin M3, Acute Promyelocytic Leukemia (APL), is treatable w/ ATRA (all trans retinoic acid) unlike other AMLs Chromosomal abnormality, t(15,17), is associated w/ good prognosis Auer rods are present in blast cells DIC is assoc. w/ this type of AML Treatment: ATRA + chemo: ATRA is a differentiation agent (makes blast cancer cells more mature)- only drug that does this Complete remission in 70-80% of APL pts and cure in 30-35% of pts. 1
2 Someone forgot to take the sticky note off this part when they copied it so we were missing a few words, I did the best I could DEFINITIONS Induction: (A.K.A. remission induction) therapy directed at getting rid of all visible leukemia (usually involves the 2 drug chemotherapy listed above for AML) Consolidation: High dose treatment is given after induction of remission to destroy remaining leukemia cells and prevent a relapse. Treatment options in AML are high-dose cytarabine and either allogenic (from genetically different individual of the same species) or autologous (from self) stem cell transplant Maintenance: An example is ATRA used to treat M3 AML, the goal is to prevent recurrence w/ low dose treatment MYELODISPLASIA (MDS) -Stem cell disorder that can progress to acute leukemia (AML) Disease of the elderly -The FAB classification (1999) of RARS, RA, RAEB, RAEB-t and CML -Prognosis based on IPSS scoring system (1997-table below) -Treatment: Supportive w/ transfusions and erythropoietin Allogenic Bone Marrow Transplant for a younger pt. -Alkylating agents (see Scofield s lect 9/22 e.g., cytoxan, chlorambucil) and radiation therapy can cause MDS International Prognosis Scoring System (IPSS) in MDS Variable Bone Marrow Blasts (%) < Karyotype* Good Intermediate Poor - - Cytopenias 0/1 2/ *Karyotype def: Good-Normal;-Y; del(5q); del(20q) Poor-Complex ( 3 abnormalities); abnormal chromosome 7 Intermediate- all others Risk Group/IPSS score Low / 0 Intermediate-1 / Intermediate-2 / High / Cytopenia def: RBC Hgb < 10g/dl WBC- Absolute neutrophil ct. < 1800 / µl Median Survival (in Years) in Myelodysplastic Syndrome According to IPSS and Age IPSS risk group Age 60 Age > 60 Age > 70 Low Intermediate Intermediate High Now on to the power point slides (he skipped a lot of slides especially pictures) 1.2 Presentation of Acute Leukemia: weakness, pallor (pale), fever, infection and bleeding -w/ bleeding you can get petechiae (tiny red dots due to low platelets) or purpura (big red dots due to low platelets 1.3 CBC in Acute Leukemia: will show the following, -Increased WBC: particularly blasts -Anemia -Thrombocytopenia -Rare cases of pancytopenia (reduction of all blood cells) which also causes a low Hgb 2
3 2.1 Physical Findings in Acute Leukemia: Splenomegaly, lymphadenopathy, skin involvement called leukemia curtis, and gum hypertrophy mainly associated w/ monocytic leukemia 2.2 Work up of Acute Leukemia: -CBC, chemistries -Coagulation tests to R/O DIC (DIC is more common in M3 AML) -HLA typing to determine if the pt is a potential transplant candidate -Bone marrow tests: morphology, histochemistry, immunophenotyping, cytogenetics (most important) -Chest X-ray -Spinal tap indicated w/ high-risk pts. 2.3 Supportive Care Acute Leukemia: -Leukapherisis (mechanically filter out WBC) when the pt has >100,000 blasts to prevent coagulation and clotting -Prevent tumor lysis syndrome by giving: 1. IV hydration, 2. Sodium bicarbonate to alkalinize urine, 3. Allopurinol *Tumor lysis syndrome occurs when chemo. is too effective; breaking down the cells to quickly will cause a build up of the broken down cellular products in the kidneys. This syndrome is a problem in Acute Leukemia, Burkitt lymphoma and cancers where chemo works very quickly. -Blood transfusion is done w/ Hgb <8 -Platelet transfusion is done w/ platelet ct < 10, Treatment of Acute Leukemia (repeated from the first 2 page handout---remember these) Induction: one cycle of therapy to obtain complete remission which is followed by consolidation The purpose of therapy is to get complete remission, w/out this treatment is worthless. Even w/complete remission most people relapse so consolidation is very important. Get the pt. in complete remission and keep them there. This is very difficult especially w/ acute leukemia. Consolidation: 2-3 rounds of high dose therapy to consolidate complete remission Maintenance: low dose therapy to maintain complete remission W/ acute leukemia, therapy usually gets 70% of adult pts in complete remission however, only about 30% will be cured. Which means that over 50% of pts will relapse. Treatment of a relapsed pt: Use of bone marrow/stem cell transplant (allogenic(from same speicies), autologous (self), or unrelated) for consolidation or relapse *review AML on first page of handout : Acute lymphocytic (lymphoblastic) leukemia (ALL) and pretty picture of it. 4.1: Poor prognosis Childhood ALL: well studied and more advances have been made for childhood cancers unlike adult cancers -ages less than 1 and more than 9 (ages 2-8 yo have good prognosis) -WBC> 50,000 -Slow early response therapy -CML: Phil. Chrom (9,22) occurs in 25% of ALL cases -Rearrangement MLL (11q23)- secondary ALL -CNS, testicular disease -Hypodiploidy *this stuff is not on his handout so he gave us a hint that he probably won t test on it 4.2: Induction therapy w/ Childhood ALL Good risk pts: treat w/ Vaincristine and Prednisone and the complete remission rate is > 95% High risk pts: treat w/ add anthracyline to above and may also give radiation therapy however this is used less because secondary side effects can be bad like growth and mental retardation. 4.3: Consolidation w/ Childhood ALL Good Risk pts: high does Methotrexate High Risk pts: treatment is very, very complicated (5-10 drugs given over 2-5 yrs.) 3
4 5.1: Maintenance Therapy w/ Childhood ALL: give daily oral mercaptopurine and sometimes weekly oral methotrexate. 5.2: Relapse w/ Childhood ALL: give pt. transplant or reinduce w/ chemotherapy. Once you relapse your prognosis is much worse. A short story from Dr. S. *dose reduction: After chemo., pt gets sick. With adults, oncologists reduce the dose however, pediatric oncologists ignore the sickness and keep pushing the high dose treatment. A recent study showed that when teenagers were treated by pediatric oncologist their results were good which suggests (according to Dr. S) that high dose therapy is better. Or pediatric oncologists are better, I am not sure. 5.3: Poor Prognosis ALL in Adults -age > 25 -Elevated beta-2 microglobulin -CML - Phil. Chrom. (9,22) or bcr-abl fusion gene -t(4,11) -Late B cell (surface immunoglobulin, t (8,14), L3 morphology) *adults do worse overall than kids 6.1: Treatment of B cell ALL: treat like aggressive non-hodkin s Lymphoma (burkitt s) -give Cyclophosphamide, high dose methrexate *side note: the difference between lymphoma and leukemia -Lymphoma: cancer in the lymph nodes -Lukemia: cancer in the blood Very often cancer in the lymph nodes goes into the blood and vise versa. 6.2: Induction w/ Adult ALL (again he is not holding us responsible for this, stick the summary on first 2 pgs) -Prednisone, Vincristine, Anthracycline: some regimens add L-asparaginase, cyclophosphamide -CNS prophylaxis: Intra-thecal methotrexate and optional cranial irradiation, high dose systemic methotrexate 6.3: Post Remission Therapy for Adults w/ ALL -Better results w/ aggressive multi-agent chemo. (very complicated but effective) T cell ALL has a better prognosis -Bone marrow transplant results are similar to aggressive chemo. 7.1: Prognosis for ALL: 75% of kids go into long term remission w/ therapy whereas only 40% of adults have long term remission. So it is better to be a kid with ALL than and adult Acute Myeloid Leukemia (AML) another pretty picture 8.1: Poor Prognosis w/ AML -elderly (> 60) -prior myelodysplasia; secondary to chemo. -poor preformance status -consider supportive care only: if you are old and have prior myelodysplasia the chance of cure is so small that oncologists usually do not treat these pts. 8.2: Chromosomes associated with AML prognosis Good prognosis: t (15,17)=M3 AML; t (8,21); inv 16 Poor prognosis: bcr-abl (CML) t (9,22); deletions on 5, 7; and trisomy 8 8.3: Results of AML: 70% achieve complete remission however only 30% are cured. 7% of AML pts are cured after a bone marrow transplant in second remission. Remember that this leukemia is more common and more deadly in the elderly. 4
5 9.1: Treatment of non-apl AML -Give the pt antracycline + Ara-C -Provide intensive post-remission care w/ high dose Ara-c or a bone marrow transplant -With relapse bone marrow transplant or high dose Ara-c are given 9.2: Treatment of Acute Promyelocytic Leukemia (APL) = M3 AML -remember this is due to a t (15, 17) -*ATRA is the therapy used which differentiates promyelocytes -Induction/Consolidation: ATRA+ anthracyline which results in 80% remission -Maintenance: ATRA -*Relaplse: Arsenic Trioxide, this is one instance where aresnic is a good drug 9.3: Post-induction therapy -High dose Ara-C -Transplant -*Mylotarg: Ab to CD33 w/ calicheamicin; used for 1 st relapse in elderly pts 10.1: Myeloproliferative disorders: skipped : CML pretty picture Cells found in CML: everything---bands, promeylocytes, meylocytes, metamylocytes, eosinophils, basophils, blasts AML remember is just one set of blasts 11.1 Leukemoid Rxn: How do you tell the difference between CML and a Leukemoid rxn (Stedman s def. - leukemoid rxn: leukocytosis similar to leukemia but not the result of a leukemic disease. Leukemoid rxns are sometimes observed as a feature of infectious disease, intoxication, malignant neoplasms, and acute hemorrhage or hemolysis.) With a leukemoid rxn, you are stressed out, sick, have pneumonia: with pneumonia there is not near as many cells present as w/ CML. CML has all cell types, with infection there is basically just bands and polys. -Leukemoid Rxn characteristics: WBC < 100,000; No basophils or promyelocytes; cytoplasmic inclusions (toxic granulation); elevated leukocyte alkaline phosphatase; and an underlying etiology like infection or shock 11.2: CML - Philadelphia chromosome: translocation on the long arm 9,22 Abl on 9 fused to BCR on 22 which activates abl proto-oncogenes BCR-ABL genes make tyrosine kinase (the target of GLEEVEC) 11.3: Phases of CML -Chronic: initial, no symptoms, feel fine -Accelerated: starting to gallop; peripheral blast > 15% -Blast Crisis: galloping way out of control, this is very bad, just as bad as AML, you are dead in a couple of months, at this point you have blasts > 30% *the whole purpose of therapy is to stay out of blast crisis 12.1: Clinical presentation of CML: 50% of pts show no symptoms and demonstrate an abnormal CBC only. Splenomegaly is present in 50% of cases. 90% of cases are not dx until they are in the chronic stage. Common symptoms when they present are lethargy, weakness, abdominal pain, discomfort, night sweats, and weight loss. 12.2: Treatment of Chronic Phase CML- Gleevec and Stem cell trasplant are the best way to prevent blast crisis. Interferons are not used any more. Hydrea lower blood ct in blood but does not do anything to prevent blast crisis. 12.3: GLEEVEC- if you remember one word about CML remember Gleevec - It is a tyrosine kinase inhibitor (the specific enzyme is STI-571) - With chronic cases there is a 91% response rate and a 36% complete cytogenetic response - With accelerated cases there is 17% complete cytogenetic response. - With blast crisis there is only a 7% complete cytogenetic response 5
6 13.1: Treatment of Accelerated/Blast Crisis CML- Gleevec and acute leukemia therapy along w/ transplant can be done but prognosis is pretty pore. *Remember Myeloproliferative disorders: proliferation of the normal myeloid cells Vs. Myelodysplasia: funny cells (dysplastic cells) produced by myeloid tissue 13.2 Polycythemia: too much Hgb due to increased RBC in the blood -Dx: M (Hct > 54) for F (Hct > 49) -Symptoms: facial plethora (red face), headaches, vision and metal status changes and stroke 13.3 Polycythemia Vera (true polycythemia): bone marrow spontaneously makes a lot of RBC -Serum erythropoietin is low -Splenomegaly w/ increased WBC and platelets -Mild proliferative disorder, there is often overlap w/ the other forms of polycythemia -Increased red cell mass 14.1: (this slide should be titled) Fake Plycythemia: Hgb high and low plasma vol., does not increase RBCs Other names for this are relative polycythemia, Gaisbock Syndrome, Middle age men who are hypertensive. Treatment is lose weight, and get BP down. This is really not a disease. Erythropoeitin is normal 14.2: Secondary Polycythemia: due to tissue hypoxia which stimulates erythropoietin -Stim. of epo due to tissue hypoxia can be caused by several things such as high alt., sleep apnea, COPD, cardiac shunt -causes increased red cell mass and hi serum epo -Surrepitious epo is used by long distance athletes to improve their performance (blood doping, exogenous epo, etc.) 14.3: Treatment of Polycythemia Vera: Want to prevent stroke -phleb to lower Hct below 45 -Hydroxyurea -Avoid P32 and alkylator -There is no clear use for aspirin 15.1: Essential Thrombocytosis: too many platelets -often have splenomegaly along with high Hgb and WBC due to crossover w/ polycythemia -platlet is usually > 1 million which may cause clotting and stroke becomes a major concern -Don t have to treat young asymptomatic healthy women but should treat males w/ risk factors that would cause thrombosis (get there platelet ct. down to normal) 15.2 Treatment of Essential Thrombocytosis: -Low risk: age < 60, no hx of thrombosis, platelets < 1.5 million and no CVS risk factors Don t treat, no risk -High risk: age > 60, hx of thrombosis Use hydrea or anagrelide to reduce platelets below 400, : Myelofibrosis (AMM- Anogeneic Myeloid Metaplasia) -Median age of 60 -Marrow fibrosis (scar)-would not get anything (dry tap with a bone marrow aspirate) -Extramedullary hemopoiesis, splenomegaly, tear-drops -Clonal disorder -Tx: difficult, BMT, Transfusion, spleenectomy (difficult surgery because they are huge) 16.1: Myelodysplasia- aka: Pre-leukemia -increased monocytes, chromosomal abnormalities -common in the elderly -secondary to chemo/rad- alkylating agents -Tx is difficult: can try transfusion, BMT but may progress to AML 6
7 16.2: International Prognostic Scoring System (IPSS) for Myelodiysplasia *See table on 2 nd page. Don t memorize but realize that we are able to get a prognosis for specific types of cancer. The rest of this lecture consists of review questions. I know that this type of thing is not accepted by all, but they are a good review and I think they will benefit everyone after 19 pages of power point slides. 1. The four myeloporliferative disorders are: CML, Polycythemia, ET, and AMM 2. Risk factors for Poor prognosis in AML are: increased age, bad chromosomes, prior myelodysplasia 3. Define the following: Induction, Consolidation, and Maintenance therapy: You can do it!!!! 4. How do you prevent tumor lysis syndrome: IV hydration, Allopurenol, Bicarbonate to alkalize urine 5. The chromosome for CML is : Philadelphia 6. The drug of choice for CML is: Gleevec 7. In Polycythemia Vera EPO levels are: low 8. The therapy of choice for polycythemia vera is: phlebotamy 9. The EPO levels in secondary polycythemia are: high 10. In Relative polycythemia plasma vol is: low 11. In Relative polycythemia EPO levels are: normal 12. Is myelodysplasia related to myeloproliferative disorder: no 13. What term would describe myelodysplasia for lay people: pre-leukemia 14. Do the following characteristics belong to CML or Leukemoid Rxn? Has basophils, eosinophils, promyelocytes, blasts, and philadelphia chromosome Answer: CML 15. List the facts about AML-3: DIC, Auer rods, t(15,17),and ATRA (only drug that differentiates cells) ******Know the questions above and the first two pages and you will do fine!!!!!! 7
Acute Myeloid Leukemia
Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not
Acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
Cytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
Acute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
Hematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
ACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
Myelodysplasia. Dr John Barry
Myelodysplasia Dr John Barry Myelodysplasia Group of heterogenouus bone marrow disorders that are due to a defect in stem cells. Increasing bone marrow failure leading to quan>ta>ve and qualita>ve abnormali>es
Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma
Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma Hodgkin Lymphoma Overview Case Pathophysiology Diagnosis
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
Childhood Leukemia Overview
Childhood Leukemia Overview What is childhood leukemia? Leukemia is a type of cancer that starts in early forms of blood cells. Cancer starts when cells grow out of control. Cells in nearly any part of
Update in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
Acute myeloid leukaemia (AML) in children
1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of
SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
Matthew Ulrickson, MD Banner MD Anderson Cancer Center July 29, 2015
Matthew Ulrickson, MD Banner MD Anderson Cancer Center July 29, 2015 Discuss the clinical presentation and diagnosis of acute leukemia * Discuss the impact of molecular features on prognosis and management
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
Aggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.
Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,
Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
MULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
Hematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia
John L. Kennedy, M.D. UIC College of Medicine Associate Professor of Clinical Pathology M2 Pathology Course Lead Pathologist, VA Chicago Health Care System Lecture #43 Phone: (312) 569-6690 Thursday, November
The AML Guide. Information for Patients and Caregivers. Acute Myeloid Leukemia. Emily, AML survivor
The AML Guide Information for Patients and Caregivers Acute Myeloid Leukemia Emily, AML survivor Revised 2012 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society
My Sister s s Keeper. Science Background Talk
My Sister s s Keeper Science Background Talk Outline Acute promyelocytic leukemia (APL) APL Treatment Savior Siblings In vitro fertilization (IVF) Pre-implantation Genetic Diagnosis (PGD) Risks of donating
Corporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several
Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment
MEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
What is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
The Treatment of Leukemia
The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome
The CML Guide Information for Patients and Caregivers
The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President
What is acute myeloblastic leukaemia?
Acute Myeloblastic Leukaemia What is acute myeloblastic leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines
MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
Multiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.
Multiple Myeloma Introduction Multiple myeloma is a type of cancer that affects white blood cells. Each year, thousands of people find out that they have multiple myeloma. This reference summary will help
An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
Case Conference 1/6/16
Case Conference 1/6/16 27 year old woman CC: bruising PMH: Healthy Meds: Multivitamin 4,000 IU vitamin D Fish oil Probiotic Allergies: none Family Hx: Maternal GF - Lung Ca & vasculitis Paternal GF - Heart
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML
Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma
Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively
Childhood Cancer in the Primary Care Setting
Childhood Cancer in the Primary Care Setting Mohamed Radhi, M.D. Associate Professor, UMKC Pediatric Hematology/Oncology/BMT Children s Mercy Hospital I will discuss: Overview of childhood cancer Presentation
Bone Marrow or Blood Stem Cell Transplants in Children With Severe Forms of Autoimmune Disorders or Certain Types of Cancer
Bone Marrow or Blood Stem Cell Transplants in Children With Severe Forms of Autoimmune Disorders or Certain Types of Cancer A Review of the Research for Parents and Caregivers Is This Information Right
It can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better.
Patient information from the BMJ Group It can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better. What is multiple
EDUCATIONAL COMMENTARY - GRANULOCYTE FORMATION AND CHRONIC MYELOCYTIC LEUKEMIA
LEUKEMIA Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing Education
Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
What Does My Bone Marrow Do?
What Does My Bone Marrow Do? the myelodysplastic syndromes foundation, inc. Illustrations by Kirk Moldoff Published by The Myelodysplastic Syndromes Foundation, Inc. First Edition, 2009. 2012. Table of
Leukemia. Leukemia vs lymphoma The major types of leukemia are based on whether the disease is: Acute or chronic Lymphocytic or myeloid
Leukemia Leukemia vs lymphoma The major types of leukemia are based on whether the disease is: Acute or chronic Lymphocytic or myeloid Acute vs chronic leukemia rapid increase in immature blood cells.
Exercise 9: Blood. Readings: Silverthorn 5 th ed, 547 558, 804 805; 6 th ed, 545 557, 825 826.
Exercise 9: Blood Readings: Silverthorn 5 th ed, 547 558, 804 805; 6 th ed, 545 557, 825 826. Blood Typing The membranes of human red blood cells (RBCs) contain a variety of cell surface proteins called
Acute Myelogenous Leukemia
Acute Myelogenous Leukemia LEUKEMIA LYMPHOMA MYELOMA Printing of this publication made possible by an education grant from: Table of Contents Introduction 2 Normal Blood and Marrow 3 Leukemia 5 Acute Myelogenous
Oncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
The CML Guide. Information for Patients and Caregivers. Chronic Myeloid Leukemia. Matthew, CML survivor. This publication was supported by
The CML Guide Information for Patients and Caregivers Chronic Myeloid Leukemia Matthew, CML survivor This publication was supported by Revised 2014 A Message from Louis J. DeGennaro, PhD President and
Feline Lymphoma Chemotherapy and Chemotherapy Protocols
Feline Lymphoma Chemotherapy and Chemotherapy Protocols If you have reached this page, your cat probably has a definite diagnosis of feline lymphoma from your veterinarian. The information below is not
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
What is chronic lymphocytic leukaemia?
Revised October 2011 What is chronic lymphocytic leukaemia? The diagnosis of a blood cancer can be a devastating event for patients, families and friends. It is therefore vital for everyone to have access
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control
Oncology Objectives Describe the etiology and pathophysiological mechanisms of cancer Discuss medical and family history findings relevant to cancer Identify general signs and symptoms associated with
Leukemia: Acute Myeloid (Myelogenous) Overview
Leukemia: Acute Myeloid (Myelogenous) Overview This overview is based on the more detailed information in our document, Leukemia- Acute Myeloid. You can get this document and other information by calling
Interpretation of Laboratory Values
Interpretation of Laboratory Values Konrad J. Dias PT, DPT, CCS Overview Electrolyte imbalances Renal Function Tests Complete Blood Count Coagulation Profile Fluid imbalance Sodium Electrolyte Imbalances
Understanding Leukemia
Understanding Leukemia Ray, CML survivor Revised 2012 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is the world s largest
2015 RN.ORG, S.A., RN.ORG, LLC
Leukemia: AML, CML, ALL and CLL WWW.RN.ORG Reviewed September, 2015, Expires September, 2017 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2015 RN.ORG,
亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010
NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010 Slide 081 Available data: 72 year-old female Diagnosis: MDS to AML WBC 51.0 x 10 9 /L RBC 3.39 x 10 12 /L
Blood. Functions of Blood. Components of Blood. Transporting. Distributing body heat. A type of connective tissue. Formed elements.
Blood Functions of Blood Transporting nutrients respiratory gases waste products Distributing body heat Components of Blood A type of connective tissue Formed elements Living blood cells Plasma Nonliving
Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
Controversies in the management of patients with PMF 0/1
State of the art treatments of patients with MPNs Turracher Höhe 2010 Controversies in the management of patients with PMF 0/1 Heinz Gisslinger Medical University of Vienna Divison for Hematology, Vienna
PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION
PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION This booklet was designed to help you and the important people in your life understand the treatment of high dose chemotherapy with stem cell support: a procedure
Blood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
Guidelines for the Management of Acute Myelogenous Leukemia in Adults
Guidelines for the Management of Acute Myelogenous Leukemia in Adults Guidelines for the Management of Acute Myelogenous Leukemia in Adults - Guidelines for the Management of Acute Myelogenous Leukemia
Other treatments for chronic myeloid leukaemia
Other treatments for chronic myeloid leukaemia This information is an extract from the booklet Understanding chronic myeloid leukaemia. You may find the full booklet helpful. We can send you a copy free
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute
Hepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
Answering your questions on Chronic Myeloid Leukaemia (CML)
Answering your questions on Chronic Myeloid Leukaemia (CML) Your guide to understanding CML and Glivec (imatinib) treatment The information in this booklet is designed to help you understand chronic myeloid
Thymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.
Thymus Cancer Introduction Thymus cancer is a rare cancer. It starts in the small organ that lies in the upper chest under the breastbone. The thymus makes white blood cells that protect the body against
Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
